- cafead Jun 08, 2022 at 11:03: PM
via Gene editing biotech Precision BioSciences is touting phase 1/2 results as proof it could bring the first off-the-shelf CAR-T drug to market.
The promising, albeit early, data from the study released Wednesday found that 100% of evaluable patients with either non-Hodgkin lymphoma or B-cell acute lymphoblastic leukemia who had relapsed following CAR-T treatments, and who had received an average of five lines of prior treatment, responded to Precision’s lead therapy PBCAR0191.
article source
The promising, albeit early, data from the study released Wednesday found that 100% of evaluable patients with either non-Hodgkin lymphoma or B-cell acute lymphoblastic leukemia who had relapsed following CAR-T treatments, and who had received an average of five lines of prior treatment, responded to Precision’s lead therapy PBCAR0191.
article source